New

Europe Neoantigens Market

2021

Europe Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Publication Month: Nov 2021 | Report Code: TIPRE00025574 | No. of Pages: 76 | Category: Pharmaceuticals | Status: Published

Market Insights

Europe Neoantigens Market to Grow at a CAGR of 31.7% to reach US$ 341,855.35 thousand from 2021 to 2028

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The neoantigens market in Europe is expected to grow from US$ 86,165.00 thousand in 2023 to US$ 341,855.35 thousand by 2028; it is estimated to grow at a CAGR of 31.7% from 2023 to 2028.


The UK, Germany, and France are major economies in Europe. Evolution in neoantigen vaccines against cancer is the major factor driving the growth of the Europe neoantigens market. Developments in biotechnology have led to rise in acceptance for immunotherapy, further driving its use in personalized medicines. Immunotherapy is widely used to treat cancer; a few the immunotherapy procedures involve the use of neoantigens, the antigens present on the surface of cancer cells. Therefore, applications of neoantigens are being widely studied to treat cancer. The uniqueness of neoantigens allows researchers to identify patients’ immune system and find antigens to target cancer cells without disturbing healthy cells. The developments in immunotherapy caught pace after 2015, when the first clinical trial of neoantigen vaccine was performed. In 2017, two additional clinical trial studies were published by Neon Therapeutics that proved the efficacy of neoantigen vaccine treat melanoma (skin cancer) in humans. The positive results of clinical trials have attracted various startups to discover and develop neoantigen-based cancer therapeutics. Many companies have shown interest in the development of neoantigens. Following are few examples of companies involved in the development of neoantigens.

• BioNTech SE is a German company operating in the neoantigen vaccines market. BioNTech SE has developed Individualized Vaccines Against Cancer (IVAC) Mutanome platform that engineer RNA molecules to produce customized neoantigen vaccine. The clinical trials for IVAC that target triple negative breast cancer, multiple tumor types, and melanoma are pending.

• The ATLAS platform of Genocea Biosciences uses an ex-vivo method to develop neoantigen vaccines. Genocea Biosciences has raised ~US$ 91 million funds from investors such as Polaris Partners, GlaxoSmithKline, and Johnson & Johnson Innovation to develop its neoantigen cancer vaccine—GEN-009. Currently in the Phase 1a/2 clinical trial, the vaccine is designed to treat melanoma, lung cancer, and carcinomas.

• Gritstone Oncology uses its AI platform—EDGE—to develop neoantigen vaccines using an in-silico approach. The company has developed two products GRANITE-001 and SLATE-001. GRANITE-001 is designed as an individual treatment based on patient’s specific tumor type, whereas SLATE-001 is formulated as a common neoantigen vaccine that can be used for multiple patients showing similar neoantigen.

• Agenus Inc. has developed AutoSynVax (ASV) neoantigen vaccine that is administered with an adjuvant QS-21 Stimulon to treat solid tumors. At present ASV is in the Phase 1 clinical trial in USA.

• Since 2016, Moderna, Inc. is involved in clinical trials for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda by Merck. In November 2020, Moderna, Inc. published updates about its cancer vaccines stating that administrating mRNA-4157 in combination with Keytruda is well tolerated at all dose levels and has produced responses in patients.

Such developments in the neoantigen vaccines against cancer are fueling the market growth.

In Europe, there is an exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of May 6th, 2020, Spain, the UK, Italy, Germany, and France recorded 3,551,262; 4,425,940; 4,070,400; 3,469,448; and 5,706,378, COVID-19 cases, respectively, and the deaths toll is also high in these countries. As per the news article, due to COVID-19 emergency, access to chemotherapy, scans, transplants, and surgery has become difficult for thousands of cancer patients in Italy. According to the research led by Codice Viola, charity that supports pancreatic cancer patients found that more than 500 breast or pancreatic patients’ appointments for chemotherapy or radiotherapy were postponed. Additionally, 64% of surgical procedures were postponed and more than half of the follow-up appointments rescheduled. Additionally, in Europe, many of the cancer vaccine development companies have been directed to develop COVID-19 vaccine. For instance, on April 2020, NEC announced that, after its neoantigen cancer vaccine project, it is planning to develop COVID-19 vaccine using AI with a close collaboration with NOI, a biotechnology subsidiary located in Oslo, Norway. Also, patient enrollment in clinical trials has been significantly declined. These factors are likely to have negative impact on the market growth.

Get more information on this report :


Europe Neoantigens Market Segmentation

Europe Neoantigens Market – By Treatment

  • Combination Therapy
  • Mono Therapy

Europe Neoantigens Market – By Therapeutic Specialty

  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumors
  • Urinary System Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others

Europe Neoantigens Market– By Country

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Europe Neoantigens Market-Companies Mentioned

  • Achilles Therapeutics plc
  • Frame Cancer Therapeutics
  • Genocea
  • Immunicum AB
  • Medigene AG
  • Moderna, Inc

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Neoantigens Market – By Treatment

1.3.2 Europe Neoantigens Market – By Therapeutic Specialty

1.3.3 Europe Neoantigens Market– By Country

2. Europe Neoantigens Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Neoantigens Market– Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Europe PEST Analysis

4.3 Expert Opinion

5. Neoantigens Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Evolution in Neoantigen Vaccines Against Cancer

5.1.2 Rising Prevalence of Cancer

5.2 Market Restraints

5.2.1 Possible Side Effects Associated with Neoantigen Vaccines

5.3 Market Opportunities

5.3.1 Application of Next-generation Sequencing for Neoantigen Identification

5.4 Future Trends

5.4.1 Use of AI in Neoantigen Vaccine Development

5.5 Impact Analysis

6. Neoantigens Market – Europe Analysis

6.1 Europe Neoantigens Market Revenue Forecast and Analysis

7. Europe Neoantigens Market Analysis – By Treatment

7.1 Overview

7.2 Europe Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

7.3 Combination Therapy

7.3.1 Overview

7.3.2 Combination Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

7.4 Mono Therapy

7.4.1 Overview

7.4.2 Mono Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8. Europe Neoantigens Market Analysis – By Therapeutic Specialty

8.1 Overview

8.2 Europe Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

8.3 Gastrointestinal Cancer

8.3.1 Overview

8.3.2 Gastrointestinal Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.4 Lung Cancer

8.4.1 Overview

8.4.2 Lung Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.5 Solid Tumors

8.5.1 Overview

8.5.2 Solid Tumors: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.6 Urinary System Cancers

8.6.1 Overview

8.6.2 Urinary System Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.7 Melanoma

8.7.1 Overview

8.7.2 Melanoma: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.8 Head and Neck Cancers

8.8.1 Overview

8.8.2 Head and Neck Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.9 Others

8.9.1 Overview

8.9.2 Others: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

9. Europe Neoantigens Market – Country Analysis

9.1 Europe: Neoantigens Market

9.1.1 Overview

9.1.2 Europe: Neoantigens Market, by Country, 2023 & 2028(%)

9.1.3 Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.1 Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.2 Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.3 Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.4 France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.1 France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.2 France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.3 France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.5 UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.1 UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.2 UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.3 UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.6 Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.1 Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.2 Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.3 Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.7 Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.1 Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.2 Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.3 Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.8 Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.1 Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.2 Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.3 Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

10. Impact Of COVID-19 Pandemic on Europe Neoantigens Market

10.1 Europe: Impact Assessment of COVID-19 Pandemic

11. Neoantigens Market–Industry Landscape

12. Company Profiles

12.1 Achilles Therapeutics plc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Frame Cancer Therapeutics

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Genocea

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Immunicum AB

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Medigene AG

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Moderna, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

13. Appendix

13.1 About the Insight Partners

13.2 Glossary of Terms

LIST OF TABLES

Table 1. New Cancer Cases Registered Worldwide, 2020

Table 2. Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

Table 3. Incidence, Mortality and Prevalence by cancer site, 2020, Germany

Table 4. Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 5. Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 6. Incidence, Mortality and Prevalence by cancer site, 2020, France

Table 7. France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 8. France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 9. UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 10. UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

Table 11. Incidence, Mortality and Prevalence by cancer site, 2020, Italy

Table 12. Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 13. Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 14. Incidence, Mortality and Prevalence by cancer site, 2020, Spain

Table 15. Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 16. Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 17. Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 18. Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 19. Market Developments Done By Companies

Table 20. Glossary of Terms, Neoantigens Market

LIST OF FIGURES

Figure 1. Europe Neoantigens Market Segmentation

Figure 2. Europe Neoantigens Segmentation, By Country

Figure 3. Europe Neoantigens Market Overview

Figure 4. Combination Therapy Segment Holds Largest Share of Europe Neoantigens Market

Figure 5. Germany to Show Remarkable Growth During Forecast Period

Figure 6. Europe: PEST Analysis

Figure 7. Expert Opinion

Figure 8. Europe Neoantigens Market Impact Analysis of Drivers and Restraints

Figure 9. Europe Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028

Figure 10. Europe Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

Figure 11. Combination Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 12. Mono Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 13. Europe Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

Figure 14. Gastrointestinal Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 15. Lung Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 16. Solid Tumors: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 17. Urinary System Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 18. Melanoma: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 19. Head and Neck Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 20. Others: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 21. Europe: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 22. Europe: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 23. Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 24. France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 25. UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 26. Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 27. Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 28. Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 29. Impact of COVID-19 Pandemic in European Country Markets

  1. Achilles Therapeutics plc
  2. Frame Cancer Therapeutics
  3. Genocea
  4. Immunicum AB
  5. Medigene AG
  6. Moderna, Inc
  • To understand the Europe neoantigens market landscape and identify market segments that are most likely to guarantee a strong return
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe neoantigens market
  • Efficiently plan M&A and partnership deals in Europe neoantigens market by identifying market segments with the most promising probable sales
  • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe neoantigens Market
  • Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
TIPRE00025574
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.